Graphite One reports its third defence logistics development agreement since 2023, with no value, payment terms or testing ...

Resolution Minerals reports three gold holes at Golden Gate North in Idaho, supporting a zone at least 500 metres long ahead ...

Xencor chose an XmAb819 dose after five of 11 patients responded; severe treatment-related events affected 72.1 per cent ...

Ivonescimab plus chemotherapy cut death risk by 25 per cent versus durvalumab plus chemotherapy in a Chinese Phase 3 ...

BioNTech and Bristol Myers report 36.7% confirmed response with pumitamig plus docetaxel in 30 evaluable patients, without a ...

Genmab reports 75 per cent first-line response with petosemtamab and chemotherapy; uncontrolled Phase 2 findings include ...

Lilly reports a 62% response rate with an olomorasib lung-cancer combination. Randomized SUNRAY-01 results are expected in ...

Climb Bio reported immunologic remission in five of 13 pMN patients at 12 weeks. Its uncontrolled Phase 2 trial has more data ...

Canopy Growth shareholders authorized a 1-for-5 to 1-for-15 consolidation on Oct. 23, leaving the ratio and implementation to ...

Cambria Gold Mines reports 98.56 grams per tonne gold over 8.2 metres at Silver Coin as drilling informs its Premier restart ...

Teck says Highland Valley Copper is operating at reduced capacity after a strike by USW Local 7619, ahead of Oct. 29 results.

Genmab will run a Phase 1/2 trial of petosemtamab, Incyte’s KRAS G12D inhibitor and chemotherapy; trial timing and endpoints remain undisclosed.